A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes
Clinical trial NCT01427699 · COMPLETED
Trial details
- NCT number
- NCT01427699
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-30
- Primary completion
- 2012-10-31
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.